SAN DIEGO, July 7, 2026, 02:02 PDT
- Crinetics traded at $83.60 premarket, about 1.7% under Vertex’s $85 per share cash bid. The stock finished Monday at $42.03.
- The merger doesn’t depend on financing, includes a $4.5 billion bridge loan backstop, and aims to close in the third quarter.
- Vertex is paying $8.8 billion net for the deal, valuing what it says is a $5 billion-plus annual sales peak at under 1.8 times that estimate.
Crinetics Pharmaceuticals Inc NASDAQ:CRNX jumped from a biotech launch story to a cash deal after Vertex Pharmaceuticals Inc NASDAQ:VRTX said it will buy the San Diego company for $85 a share.
Shares traded at $83.60 as of 4:28 a.m. ET, up 98.9% premarket. The price was $1.40 per share, or 1.7%, away from the offer. On Monday, volume hit 5.42 million shares, or 420% of the 65-day average, before the deal reset the stock.
The return now comes down more to timing and less to Palsonify prescription numbers. If the all-cash deal wraps up by Sept. 30, end of Q3, the $1.40 spread would mean roughly 7.4% annualized before fees and trading. If it pushes out to the Jan. 6, 2027 outside date in the merger contract, annualized return drops to around 3.4%. The deal has a three-month extension option if certain terms are met.
| Closing forecast | Days from July 7 | Gross spread at $83.60 | Annualized gross return |
|---|---|---|---|
| Closing by Sept. 30, 2026 | 85 | 1.7% | 7.4% |
| Jan. 6, 2027 outside date | 183 | 1.7% | 3.4% |
| Apr. 6, 2027 extended outside date | 273 | 1.7% | 2.2% |
The spread looks tight compared with the break fee. Crinetics could owe Vertex $350.5 million if the deal gets scrapped for certain reasons. With about 117.6 million shares and awards implied by the $10 billion valuation at $85 a share, that works out to around $2.98 per share—well over the current $1.40 spread.
| Deal math | Figure |
|---|---|
| Equity counted at offer | About 117.6 million shares and award equivalents |
| Spread from offer now | $1.40 a share |
| Total spread at deal share count | About $165 million |
| Breakup fee | $350.5 million |
| Breakup fee per deal share | About $2.98 |
This is key for investors, since the market is pricing in the deal closing and not re-rating CRNX as an independent stock. MarketWatch shows 105.44 million Crinetics shares outstanding, but the $10 billion equity value on this deal points to a bigger diluted total. According to the SEC filing, unvested options and RSUs will vest by closing, with in-the-money awards to get cashed out.
The deal still needs Crinetics shareholder approval plus expiration or end of the Hart-Scott-Rodino waiting period, as well as some foreign clearances and no legal roadblocks. It doesn’t have a financing condition, according to the SEC filing. Vertex arranged a $4.5 billion unsecured bridge loan for 364 days with Bank of America, BofA Securities and Morgan Stanley Senior Funding.
Vertex is set to pay roughly $10 billion in equity value to buy the company, or $8.8 billion after accounting for cash on hand. That gap suggests estimated acquired cash of $1.2 billion. Vertex and Crinetics expect Palsonify and atumelnant to generate over $5 billion in combined peak annual sales, so the net price is less than 1.8 times that number.
Scotiabank’s Louise Chen said the deal brings endocrinology in as a fifth vertical, Reuters reported. Vertex CEO Reshma Kewalramani told Reuters there are no changes to Vertex’s R&D or capital allocation plans after the Crinetics deal.
Kewalramani said Vertex is able to “build on the strong momentum” from the Palsonify launch. Crinetics CEO Scott Struthers said Vertex’s “global infrastructure and commercial footprint” will help bring Crinetics’ science to more people. Vertex Pharmaceuticals Newsroom
Palsonify, also known as paltusotine, is cleared in the U.S. for adults with acromegaly who didn’t respond well to surgery or can’t get surgery, the FDA prescribing info shows. Vertex is also picking up atumelnant, in Phase 3 trials for congenital adrenal hyperplasia.
Biotech benchmarks mostly moved sideways. iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) slipped 0.25%. SPDR S&P Biotech ETF (NYSEARCA:XBI) was last up 0.16%. The stock’s move diverged from the sector.
